Bio-Rad Laboratories-B
BIO.B
365.08
0.00
0.00%
Bio-Rad Laboratories-B
US · BIO.B
#1492 by market cap
Listed 1970
365.08
0.00
0.00%
Live - 5344 symbols - heartbeat 495s ago
· 2026-10-07 19:54
After-hours
365.08
0.00%
- Market cap
- 9.76B
- P/E (TTM)i
- 44.47
- P/Bi
- 1.36
- EPSi
- 27.85
- Div yieldi
- 0.00%
- 52W posi
- 100%
Reader sentiment
Are you bullish or bearish on BIO.B?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Mixed / stable
- Total institutional ownership (as a % of shares) was little changed.
Institutional ownership
- Held by institutions
- 88.56% +0.03pp
- Institutions
- 473
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund60.17%
Private Company16.21%
Hedge Fund5.37%
Public Company5.30%
Individual/Insider4.78%
Government Pension Fund0.87%
Sovereign Wealth Fund0.42%
Insurance Company0.10%
Other6.72%
Top holders as of 2026-09-01
Blue Raven Partners, L.P.
15.18% · 4.06M sh
First Eagle Investment Management, LLC
9.75% · 2.61M sh
BlackRock
6.35% · 1.70M sh
Norman Schwartz
4.58% · 1.23M sh
Dimensional Fund Advisors
3.53% · 944.55K sh
Vanguard Capital Management, LLC
3.52% · 941.38K sh
Capital Research
3.39% · 905.94K sh
Ariel Investments, LLC
3.05% · 816.75K sh
Vanguard Portfolio Management, LLC
3.05% · 816.20K sh
UBS Asset Management
2.72% · 727.22K sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 33 buys · 17 sells
| Name | Role | Stake |
|---|---|---|
| Norman Schwartz | Chairperson & CEO | 4.58% |
| Colleen Corey | Executive Vice President of Global Human Resources | 0.07% |
| Michael Crowley | Executive Vice President of Global Commercial Operations | 0.03% |
| Allison Schwartz | Director | 0.02% |
| Roop Lakkaraju | Chief Financial Officer | 0.02% |
| Sedat Evran | Executive Vice President of Global Supply Chain | 0.01% |
| James Barry | Senior Vice President of Global Manufacturing | 0.01% |
| Jonathan DiVincenzo | President | 0.01% |
| Eva Engelhardt | Executive VP & President of the Clinical Diagnostics Group | 0.01% |
| Courtney Enloe | General Counsel | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-05 | Norman Schwartz | Chairperson & CEO | Derivative Exercise and Sale | -4,730 | $386.11 |
| 2026-09-05 | Norman Schwartz | Chairperson & CEO | Derivative Exercise and Retained | +2,834 | -- |
| 2026-09-05 | Roop Lakkaraju | Chief Financial Officer | Derivative Exercise and Sale | -1,341 | $386.11 |
| 2026-09-05 | Roop Lakkaraju | Chief Financial Officer | Derivative Exercise and Retained | +1,565 | -- |
| 2026-09-05 | Eva Engelhardt | Executive VP & President of the Clinical Diagnostics Group | Derivative Exercise and Sale | -854 | $386.11 |
| 2026-09-05 | Eva Engelhardt | Executive VP & President of the Clinical Diagnostics Group | Derivative Exercise and Retained | +1,325 | -- |
| 2026-09-05 | Allison Schwartz | Director | Derivative Exercise and Sale | -116 | $386.11 |
| 2026-09-05 | Allison Schwartz | Director | Derivative Exercise and Retained | +204 | -- |
| 2026-09-05 | James Barry | Senior Vice President of Global Manufacturing | Derivative Exercise and Sale | -839 | $386.11 |
| 2026-09-05 | James Barry | Senior Vice President of Global Manufacturing | Derivative Exercise and Retained | +1,244 | -- |
| 2026-09-05 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Sale | -606 | $386.11 |
| 2026-09-05 | Sedat Evran | Executive Vice President of Global Supply Chain | Derivative Exercise and Retained | +1,285 | -- |
| 2026-09-05 | Courtney Enloe | General Counsel | Derivative Exercise and Sale | -551 | $386.11 |
| 2026-09-05 | Courtney Enloe | General Counsel | Derivative Exercise and Retained | +902 | -- |
| 2026-09-04 | Jonathan DiVincenzo | President | Derivative Exercise and Sale | -668 | $386.11 |
| 2026-09-04 | Jonathan DiVincenzo | President | Derivative Exercise and Retained | +1,044 | -- |
| 2026-09-04 | Rajat Mehta | Executive Vice President of Global Commercial Operations | Derivative Exercise and Sale | -737 | $386.11 |
| 2026-09-04 | Rajat Mehta | Executive Vice President of Global Commercial Operations | Derivative Exercise and Retained | +1,089 | -- |
| 2026-09-03 | Norman Schwartz | Chairperson & CEO | Other Derivative Acquisition | +17,251 | -- |
| 2026-09-03 | Roop Lakkaraju | Chief Financial Officer | Other Derivative Acquisition | +6,326 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.